PharmaDepth

Company profile

MODERNA, INC.

NASDAQ:MRNABiotechnology: Biological Products (No Diagnostic Substances)

Drug pipeline (5)

AssetStageRevenueTrialsStatus
FLUSIVA,MFLUSIVAapproved—0—
MNEXSPIKEapproved—0—
MRESVIAapproved—0—
SPIKEVAXapproved—0—
ELASOMERANphase1_2—11active

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (96)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT06508320phase2completed2024-07-152025-09-25ModernaTX, Inc.A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
NCT04528719phase1completed2020-09-302024-07-18ModernaTX, Inc.A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive
NCT06147856phase1_2withdrawn2024-03-292026-08-10ModernaTX, Inc.A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria
NCT04975893phase2completed2021-06-182026-01-19ModernaTX, Inc.A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine
NCT05585632phase1completed2022-10-142024-02-28ModernaTX, Inc.A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old

FDA applications (4)

ApplicationApprovedTypeApplicantProducts
BLA 1258692026-08-05BLAMODERNATX, INC.
BLA 1258352025-05-30BLAMODERNATX, INC.
BLA 1257962024-05-31BLAMODERNATX, INC.
BLA 1257522022-01-31BLAMODERNATX, INC.